Ep 53: Cradle CEO Stef van Grieken on the State of AI x Bio and Selling SaaS to Pharma

Jacob sits down with Stef van Grieken, Co-Founder & CEO of Cradle. Cradle has raised over $100M from investors like IVP and Index Ventures to build and expand their AI-enabled protein engineering platform. They discuss how Cradle plans to use their new Series B funding, what’s been happening in AI bio, the technical underpinnings of Cradle’s platform, and more. [0:00] Intro [0:22] Cradle Bio's Rapid Growth and AI Innovations [0:53] The State of AI in Drug Development [1:15] Challenges and Opportunities in AI Biospace [2:21] Cradle Bio's Approach to Biologics Development [3:11] AI's Role in Hit Identification and Lead Optimization [7:42] Cradle Bio's Software and Customer Base [10:33] Inside Cradle Bio's Lab and Data Strategy [24:10] Future Directions and Protein Modalities [26:21] Navigating the Pharma SaaS Market [28:48] Challenges in Adopting New Protocols [30:15] Software vs. Service Companies [31:47] Gaps in Drug Development [33:46] Advances in AI and Bio [41:28] Future of Drug Discovery [44:18] Advice for Aspiring Bio Entrepreneurs [48:03] Quickfire Out-Of-Pocket: https://www.outofpocket.health/